Aeterna Zentaris to Present at NobleCon17
January 15 2021 - 8:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests, today announced that Dr. Klaus
Paulini, Chief Executive Officer of Aeterna, will present at
NobleCon17 - Noble Capital Markets’ Seventeenth Annual Investor
Conference on Wednesday, January 20, 2021 at 12:00 PM ET.
A high-definition, video webcast will be
available at the time of the Company’s presentation to those
registered to attend the event. The conference is virtual, with no
cost, obligation or restrictions to attend: www.noblecon17.com.
A webcast replay will be available approximately
24 hours following the presentation on the Events page in the
Investors section of the Company’s website (www.zentaris.com), and
as part of a complete catalog of presentations to be rebroadcast on
Channelchek, www.channelchek.com, next month.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
macimorelin, is the first and only U.S. FDA and European Commission
approved oral test indicated for the diagnosis of adult growth
hormone deficiency (AGHD). Macimorelin is currently marketed in the
United States under the tradename Macrilen™ through a license
agreement with Novo Nordisk where Aeterna Zentaris receives
royalties on sales. According to a commercialization and supply
agreement, MegaPharm Ltd. will seek regulatory approval and then
commercialize macimorelin in Israel and the Palestinian Authority.
Additionally, upon receipt of pricing and reimbursement approvals,
Aeterna expects that macimorelin will be marketed in Europe and the
United Kingdom through a recently established license agreement
with Consilient Health Ltd and Aeterna Zentaris will receive
royalties on sales and other potential payments.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of childhood-onset growth hormone deficiency
(CGHD), an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Asia and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking
statements (as defined by applicable securities legislation) made
pursuant to the safe-harbor provision of the U.S. Securities
Litigation Reform Act of 1995, which reflect our current
expectations regarding future events. Forward-looking statements in
this press release include those relating to Aeterna’s expectation
that, upon receipt of pricing and reimbursement approvals,
macimorelin will be marketed in Europe and the United Kingdom.
Forward-looking statements involve known and unknown risks and
uncertainties, and other factors which may cause the actual
results, performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, our ability to obtain receipt of pricing and
reimbursement approvals as well as those risks discussed in our
Annual Report on Form 20-F, under the caption "Key Information Risk
Factors" filed with the relevant Canadian securities regulatory
authorities in lieu of an annual information form and with the U.S.
Securities and Exchange Commission. Given the uncertainties and
risk factors, readers are cautioned not to place undue reliance on
these forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce any revisions to
any of the forward-looking statements contained herein to reflect
future results, events or developments, unless required to do so by
a governmental authority or applicable law.
Investor Contact: Jenene Thomas JTC Team T
(US): +1 (833) 475-8247 E: aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024